TE
Tema ETFs Portfolio holdings
AUM
$377M
This Quarter Return
+13.47%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$377M
AUM Growth
+$41.9M
(+13%)
Cap. Flow
+$8.19M
Cap. Flow
% of AUM
2.17%
Top 10 Holdings %
Top 10 Hldgs %
20.9%
Holding
176
New
29
Increased
67
Reduced
61
Closed
11
Top Buys
| 1 |
Eaton
ETN
|
$10M |
| 2 |
Cognex
CGNX
|
$7.72M |
| 3 |
CRH
CRH
|
$5.63M |
| 4 |
Linde
LIN
|
$5.21M |
| 5 |
Johnson Controls International
JCI
|
$3.81M |
Top Sells
| 1 |
Vulcan Materials
VMC
|
$5.25M |
| 2 |
APi Group
APG
|
$4.9M |
| 3 |
Rockwell Automation
ROK
|
$4.88M |
| 4 |
Clean Harbors
CLH
|
$4.34M |
| 5 |
Applied Industrial Technologies
AIT
|
$3.95M |
Sector Composition
| 1 | Industrials | 38.16% |
| 2 | Healthcare | 30.66% |
| 3 | Technology | 10.25% |
| 4 | Utilities | 8.88% |
| 5 | Materials | 5.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Keysight
KEYS
$28.3B
| $635K | 0.17% |
+3,875
| New | +$635K |
|
127
JPMorgan Chase
JPM
$826B
| $630K | 0.17% |
+2,173
| New | +$630K |
|
|
AAPG
128
Ascentage Pharma Group International American Depository Shares
AAPG
$3.63B
| $610K | 0.16% |
+15,495
| New | +$610K |
|
129
Guardant Health
GH
$7.49B
| $591K | 0.16% |
11,350
+1,190
| +12% | +$61.9K |
|
130
Icon
ICLR
$13.1B
| $576K | 0.15% |
+3,959
| New | +$576K |
|
131
Arrowhead Research
ARWR
$3.94B
| $559K | 0.15% |
35,359
+5,466
| +18% | +$86.4K |
|
132
Akero Therapeutics
AKRO
$3.66B
| $546K | 0.15% |
10,239
-1,539
| -13% | -$82.1K |
|
133
Madrigal Pharmaceuticals
MDGL
$9.72B
| $545K | 0.14% |
1,801
-477
| -21% | -$144K |
|
134
Scholar Rock
SRRK
$3.14B
| $537K | 0.14% |
+15,153
| New | +$537K |
|
135
Arvinas
ARVN
$564M
| $531K | 0.14% |
72,114
+33,799
| +88% | +$249K |
|
136
Viking Therapeutics
VKTX
$2.98B
| $524K | 0.14% |
19,755
+524
| +3% | +$13.9K |
|
137
Mirum Pharmaceuticals
MIRM
$3.74B
| $506K | 0.13% |
9,947
-1,485
| -13% | -$75.6K |
|
138
Neurocrine Biosciences
NBIX
$13.7B
| $491K | 0.13% |
3,904
| – | – |
|
139
Arcus Biosciences
RCUS
$1.21B
| $486K | 0.13% |
59,662
+44,411
| +291% | +$362K |
|
140
Teva Pharmaceuticals
TEVA
$21.5B
| $484K | 0.13% |
28,861
| – | – |
|
141
Insmed
INSM
$30.4B
| $480K | 0.13% |
4,765
-4,416
| -48% | -$444K |
|
142
Structure Therapeutics
GPCR
$1.13B
| $475K | 0.13% |
22,880
+290
| +1% | +$6.02K |
|
143
Illumina
ILMN
$15.1B
| $461K | 0.12% |
4,835
+1,322
| +38% | +$126K |
|
144
West Pharmaceutical
WST
$17.8B
| $433K | 0.11% |
1,977
-292
| -13% | -$63.9K |
|
145
Becton Dickinson
BDX
$54.4B
| $420K | 0.11% |
2,438
+186
| +8% | +$32K |
|
146
Replimune Group
REPL
$449M
| $380K | 0.1% |
40,906
+3,384
| +9% | +$31.4K |
|
147
Stryker
SYK
$150B
| $355K | 0.09% |
898
+100
| +13% | +$39.6K |
|
148
Schrodinger
SDGR
$1.39B
| $352K | 0.09% |
17,493
+1,036
| +6% | +$20.8K |
|
149
Relay Therapeutics
RLAY
$697M
| $336K | 0.09% |
97,150
+8,040
| +9% | +$27.8K |
|
150
Cullinan Oncology
CGEM
$417M
| $321K | 0.09% |
42,692
+3,528
| +9% | +$26.6K |
|